GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Piramal Pharma Ltd (NSE:PPLPHARMA) » Definitions » Cash, Cash Equivalents, Marketable Securities

Piramal Pharma (NSE:PPLPHARMA) Cash, Cash Equivalents, Marketable Securities : ₹6,431 Mil (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Piramal Pharma Cash, Cash Equivalents, Marketable Securities?

Piramal Pharma's quarterly cash, cash equivalents, marketable securities declined from Sep. 2023 (₹6,653.10 Mil) to Dec. 2023 (₹0.00 Mil) but then increased from Dec. 2023 (₹0.00 Mil) to Mar. 2024 (₹6,431.40 Mil).

Piramal Pharma's annual cash, cash equivalents, marketable securities increased from Mar. 2022 (₹3,793.90 Mil) to Mar. 2023 (₹7,346.70 Mil) but then declined from Mar. 2023 (₹7,346.70 Mil) to Mar. 2024 (₹6,431.40 Mil).


Piramal Pharma Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Piramal Pharma's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Piramal Pharma Cash, Cash Equivalents, Marketable Securities Chart

Piramal Pharma Annual Data
Trend Mar21 Mar22 Mar23 Mar24
Cash, Cash Equivalents, Marketable Securities
1,623.70 3,793.90 7,346.70 6,431.40

Piramal Pharma Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7,346.70 - 6,653.10 - 6,431.40

Piramal Pharma Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Piramal Pharma  (NSE:PPLPHARMA) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Piramal Pharma Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Piramal Pharma's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Piramal Pharma (NSE:PPLPHARMA) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Piramal Pharma Ltd (NSE:PPLPHARMA) » Definitions » Cash, Cash Equivalents, Marketable Securities
Traded in Other Exchanges
Address
Piramal Ananta, Agastya Corporate Park, Opposite Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai, MH, IND, 400070
Piramal Pharma Ltd offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 15 global facilities and a global distribution network in over 100 countries. It includes integrated contract development and manufacturing organization business, complex hospital generics business, and India consumer healthcare business, selling over-the-counter products in India.

Piramal Pharma (NSE:PPLPHARMA) Headlines

No Headlines